Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Chiasma partners acromegaly candidate Octreolin with Roche; terminated

Executive Summary

Israeli biotech Chiasma Inc. has licensed Roche exclusive global rights to its lead orphan drug candidate, Phase III Octreolin (octreotide). The first indication for the peptide therapeutic will be acromegaly (a growth disorder caused by the pituitary gland producing excessive growth hormone in the body), and a second potential use may be in neuroendocrine tumors, which are also related to the increased presence of growth hormone.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Large Molecule
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies